Cohance Lifesciences has received a warning letter from the US Food and Drug Administration (USFDA) concerning its Nacharam facility. The regulatory action represents a significant development for the pharmaceutical company's US operations.

Regulatory Action Details

The USFDA has issued a warning letter specifically targeting the company's Nacharam manufacturing facility. Following the regulatory review, the facility has been classified with an "Official Action Indicated" status, which typically signifies that the FDA has identified significant violations that require corrective action.

Financial Impact Assessment

The company has provided clarity on the potential financial implications of this regulatory action. According to the disclosure, US revenue generated from the affected Nacharam facility represents less than 2% of the company's total revenue. This relatively small revenue contribution suggests that the immediate financial impact on Cohance Lifesciences may be limited.

Facility Status and Operations

The "Official Action Indicated" designation typically means that the FDA has documented significant deviations from current good manufacturing practices or other regulatory requirements. This status usually requires the company to address the identified issues before the facility can resume normal operations or maintain its current regulatory standing.

The warning letter represents a formal notification from the USFDA regarding compliance issues that need immediate attention and corrective measures from the pharmaceutical manufacturer.

Cohance lifesciences Limited has successfully completed its postal ballot process for a key board appointment, with shareholders overwhelmingly approving the appointment of Mr. Himanshu Agarwal as Whole-time Director. The resolution was passed on January 22, 2026, following a comprehensive remote e-voting process that demonstrated strong shareholder participation and support.

Voting Results and Shareholder Participation

The postal ballot process concluded with decisive shareholder approval, as detailed in the company's regulatory filing to BSE and NSE on January 22, 2026. The voting results showcase broad-based support across different shareholder categories.

Director Appointment Details

The approved resolution pertains to the appointment of Mr. Himanshu Agarwal, bearing Director Identification Number (DIN) 06672915, as a Whole-time Director of the Company. This appointment represents an ordinary resolution that required simple majority approval from shareholders.

E-voting Process and Timeline

The postal ballot was conducted exclusively through remote e-voting in accordance with regulatory requirements. The process was managed by KFin Technologies Limited, serving as the Company's Registrar and Transfer Agent.

Key timeline details include:

• Postal Ballot Notice Date: December 19, 2025
• Notice Distribution: December 23, 2025
• E-voting Commencement: December 24, 2025 at 9:00 AM IST
• E-voting Conclusion: January 22, 2026 at 5:00 PM IST
• Cut-off Date: December 19, 2025

Scrutinizer Report and Compliance

The voting process was overseen by DVM Gopal (ICSI Membership No. F6280), Partner of M/s. DVM & Associates LLP, who served as the appointed Scrutinizer. The scrutinizer's report confirmed that 471 members voted in favor of the resolution representing 33,10,35,115 shares (96.862%), while 51 members voted against representing 1,07,24,106 shares (3.138%). No invalid votes were recorded during the process.

The Company published the mandatory newspaper advertisement in "Business Standard" (English Daily) and "Navshakti" (Marathi Daily) on December 24, 2025, ensuring proper public notification as required under the Companies (Management and Administration) Rules, 2014.

Regulatory Compliance and Documentation

Cohance Lifesciences Limited has made the voting results and scrutinizer's report available on its official website at https://www.cohance.com/shareholder-info-2/ and on KFin Technologies Limited's e-voting platform at https://evoting.kfintech.com/ . The company's filing was signed by Kundan Kumar Jha, Company Secretary, Compliance Officer and Head-Legal, ensuring proper regulatory compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.